National Study of Membranous Nephropathy in France with Immunological Analysis and Patient Outcomes

What this Trial Is About

Researchers are establishing a national cohort in France to study membranous nephropathy MN, a rare autoimmune kidney disease that causes nephrotic syndrome and can lead to kidney failure. This study aims to understand the incidence of MN, the presence of specific auto-antibodies anti-PLA2R1 and anti-THSD7A, clinical outcomes one year after diagnosis or relapse, environmental risk factors, genetic markers, and patient care patterns across the country. Participants diagnosed with MN will be included over one year, with an additional year of follow-up for a total of two years. Blood samples will be collected and sent to a central laboratory in Nice for detailed analysis, including testing for antibodies, epitope spreading, and genetic typing. Clinical information and lifestyle surveys will also be gathered from patients during this period. Throughout the study, participants will provide blood samples and clinical data, which researchers will use to track the diseases progression and outcomes. Key measures include incidence rates, disease evolution after one year, and associations with environmental and genetic factors. This nationwide effort will help improve understanding of MN and its management in France, with a total participation time of two years.

Immunopathological Analysis in a French National Cohort of Membranous Nephropathy